The Japan apheresis market size was worth $ 241.57 million in 2020 and is estimated to reach $ YY million by 2027, at a CAGR of 6.5% during the forecast period (2020-2027).
Apheresis is a medical procedure to remove the whole blood from a donor and separate the blood into individual components so that one particular component can be removed. The remaining blood components then are reintroduced back into the bloodstream of the patient or donor. Apheresis is used for the collection of donor blood components (such a platelets or plasma) as well as for the treatment for certain medical conditions in which a part of the blood that contains disease-provoking elements is removed. In Japan, the collection and supply of blood for use in transfusion are operated only by the Japanese Red Cross Society.
The total number of blood donors in Japan amounted to approximately 4.7 million people in 2018. Out of the number of donors, more than 68 percent donated 400 mL, around 28 percent made apheresis donations, and roughly three percent donated 200 mL. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the apheresis market in Japan. For instance,
In October 2019, Asahi Kasei Medical acquired Virusure Forschung und Entwicklung GmbH (ViruSure), an Austrian provider of biosafety testing services. It is part of a strategic expansion and reinforcement of Asahi Kasei Medical’s bioprocess business, centered on Planova™ virus removal filters used in the manufacturing process for biotherapeutics such as plasma derivatives and biopharmaceuticals.
In September 2017, Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, announced that it has expanded its collaboration with Mallinckrodt, a United Kingdom-based business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies, including the THERAKOS® CELLEX® Photopheresis System, an ECP platform.
Market Dynamics
Drivers
- Increasing incidence of hematological disorders
- Rising Advancement in technology
- Demand for blood plasma in biopharmaceutical companies
Restraints
- Risks associated with apheresis
- High cost of apheresis devices & procedures
- Lack of qualified donors
Increasing incidence of hematological disorders
The incidence of hematological disorders, such as severe leukemia, anemia, and sickle cell disease, has increased in Japan over the past few years. Physicians use apheresis to collect plasma, platelets, white blood cells, red blood cells, and other blood components for treating hematological disorders. The prevalence of anemia in Japanese women of reproductive age is 22%, which is high compared to other developed countries. About 31% of Japanese women suffer from anemia during pregnancy..The annual number of cord blood transplantation (CBT) in Japan now exceeds 1,300 and the cumulative number of CBT reached 15,544 in 2017, accounting for almost one-third of the numbers of total CBT performed worldwide.
Multiple myeloma (MM) is a hematologic malignancy associated with significant morbidity. MM is characterized by hyperproliferation of malignant plasma cells in bone marrow and immune dysfunction. In Japan, the 2016 prevalence of MM was estimated at 5.3 per 100,000 persons. The prevalence rate rises with age, with a mean age of 67 years at diagnosis. Hence, with rising incidences of hematological disorders is driving the demand for apheresis devices market in Japan.
COMPETITIVE SCENARIO
The Japan Apheresis market is highly consolidated with selected key players accounting for predominant market share. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the apheresis market in Japan. For instance, In October 2019, Asahi Kasei Medical has acquired Virusure Forschung und Entwicklung GmbH (ViruSure), an Austrian provider of biosafety testing services. It is part of a strategic expansion and reinforcement of Asahi Kasei Medical’s bioprocess business, centered on Planova™ virus removal filters used in the manufacturing process for biotherapeutics such as plasma derivatives and biopharmaceuticals. In September 2017, Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, announced that it has expanded its collaboration with Mallinckrodt, a United Kingdom-based business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies, including the THERAKOS® CELLEX® Photopheresis System, an ECP platform.